Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• DNA repair mechanisms counteract chemotherapy, reducing drug efficacy.
• Targeting DNA repair pathways is a promising strategy to improve cancer treatment outcomes.
• Nucleotide Excision Repair (NER) is a key pathway involved in resistance to DNA-damaging agents.

Purpose of the Study:

• To review the role of Nucleotide Excision Repair (NER) in cancer therapy.
• To highlight the ERCC1/XPF heterodimer as a therapeutic target.
• To summarize preclinical and clinical studies on NER inhibitors and discuss future directions.

Main Methods:

• Review of existing preclinical and clinical studies on NER inhibitors.
• Focus on the ERCC1/XPF complex and its role in DNA repair.
• Discussion of computer-aided drug design, including structure-based virtual screening.

Main Results:

• NER proteins, particularly ERCC1/XPF, are crucial for cellular resistance to alkylating agents.
• Various small molecules targeting NER proteins have shown activity in cell models.
• Preclinical and clinical studies provide a basis for NER inhibition as a therapeutic strategy.

Conclusions:

• Inhibiting NER, especially the ERCC1/XPF complex, holds potential for enhancing chemotherapy efficacy.
• While promising in vitro, further in vivo validation and clinical translation of NER inhibitors are necessary.
• Development of novel small molecule inhibitors using computational methods is ongoing.